T1	intervention 57 69	lasofoxifene
T2	eligibility 73 106	postmenopausal osteoporotic women
T3	No-of-participants 675 679	8556
T4	average-age 686 697	59-80 years
T5	control 815 822	placebo
T6	eligibility 698 741	with low bone density and normal mammograms
T7	outcome-Measure 871 927	ncidence of ER+ breast cancer and nonvertebral fractures
T8	outcome 1448 1461	Breast cancer
T10	intervention-value 1606 1609	79%
T9	outcome 1549 1602	significantly reduced the risk of total breast cancer
T11	outcome 1681 1707	ER+ invasive breast cancer
T12	intervention-value 1711 1714	83%
